A Randomized Open-label, Single Dose, 3-Period, 6-Sequence, Cross-Over Trial With Washout Periods of at Least 14 Days to Investigate the Relative Bioavailability of Apraglutide in Dual Chamber Syringes Versus the Reference Formulation in Vials Following Subcutaneous Administrations in Healthy Subjects
Latest Information Update: 29 Oct 2024
At a glance
- Drugs Apraglutide (Primary)
- Indications Graft-versus-host disease; Short bowel syndrome; Unspecified
- Focus Pharmacokinetics
- Sponsors VectivBio
Most Recent Events
- 08 Jan 2024 Status changed from recruiting to completed.
- 23 Aug 2023 New trial record